Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vitamin B12: a Biological Marker of Systemic Disease or Infection Flare-up in Patients Treated with Tocilizumab?

NCT06654154 is registered in ClinicalTrials.gov with University Hospital, Clermont-Ferrand as lead sponsor.

NCT NCT06654154
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06654154 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vitamin B12: a Biological Marker of Systemic Disease or Infection Flare-up in Patients Treated with Tocilizumab?
Lead sponsor
University Hospital, Clermont-Ferrand
Phase
Not applicable
Overall status
Recruiting
Start date
April 3, 2024
Completion date
March 31, 2029
Enrollment
56 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

level of serum vitamin b12 level (in pmol/l) if infection under tocilizumab, level of serum vitamin b12 level (in pmol/l) if relapse of (ai/id) under tocilizumab